# Who are ABL Bio's customers? Who does ABL Bio earn revenue from?
Canonical: https://valuechain.wiki/abl-bio · Facet: customers · Updated: 2026-07-12T04:17:23.858+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: ABL Bio's confirmed revenue counterparties include 일라이 릴리 plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 revenue edges, backed by 7 dated sources, 3 of them primary filings (as of 2026-07-12).

### GSK (high)
- metric: Amount 4,110,425,867,000원 · GSK 기술이전 · Total up to KRW 4,110.4bn, upfront KRW 73.9bn
- note: Licensed its Grabody-B blood-brain-barrier shuttle to GSK. Deal worth up to 4,110.4 billion won (GBP 2,140.1m), including 148.1 billion won (GBP 77.1m) in upfront and near-term milestones. GSK develops and commercialises using oligonucleotide (siRNA, ASO) and antibody modalities, with royalties on net sales.
- [mentions] IRGO (KO, research, published 2026-04-30) https://m.irgo.co.kr/IR-COMP/298380: "April 2026 analyst consensus target price 209,200 won (high 280,000, low 86,000), five analysts rating buy, with the GSK and Lilly licensing deals anchoring the valuation."
- [mentions] DART (FSS) (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312000744: "Exclusive rights transferred to GSK to develop and commercialise multiple novel-target candidates using the Grabody-B BBB shuttle platform"
- [confirms] DART (FSS) (KO, filing, published 2025-05-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20250512900217: "Total license value KRW 4,110,425,867,000 (GBP 2,140.1m); upfront and near-term milestones KRW 148,083,657,000 (GBP 77.1m)"
- [confirms] PR Newswire (EN, news, published 2025-04-07) https://www.prnewswire.com/news-releases/abl-bio-announces-grabody-b-brain-delivery-platform-license-agreement-with-gsk-to-develop-novel-medicines-for-neurodegenerative-diseases-302421544.html: "GSK to develop neurodegenerative medicines using Grabody-B; up to GBP 77m upfront/near-term, deal valued at up to GBP 2.075bn (~US$2.65bn)."

### 일라이 릴리 (high)  → /lilly-eli.md
- metric: Amount 3,807,246,400,000원 · 릴리 기술이전 · Total up to KRW 3,807.2bn, upfront KRW 58.5bn
- note: Licensed its Grabody-B platform to Eli Lilly with joint early research. Deal worth up to 3,807.2 billion won (USD 2,602m); the 58.5 billion won (USD 40m) upfront was received on 6 Jan 2026. Lilly develops multiple undisclosed targets across modalities, with royalties on net sales.
- [confirms] DART (FSS) (KO, filing, published 2025-11-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20251112900144: "Total license value KRW 3,807,246,400,000 (USD 2,602m); upfront KRW 58,528,000,000 (USD 40m)"
- [confirms] The Korea Economic Daily (KED Global) (EN, news, published 2025-11-12) https://www.kedglobal.com/bio-pharma/newsView/ked202511120004: "ABL Bio signs a Grabody license deal with Eli Lilly worth up to $2.6bn, capping a record year for Korean biotech exports."

### 사노피 (high)
- note: Licensed ABL301, its Parkinson's bispecific (alpha-synuclein x IGF1R), to Sanofi (via subsidiary Genzyme). Deal worth about USD 1.06bn with a USD 75m upfront. Sanofi runs the subsequent clinical development on its own.
- [confirms] DART (FSS) (KO, filing, published 2026-03-12) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260312000744: "ABL301 Parkinson's bispecific licensed to Sanofi; the agreement was executed through Genzyme Corporation, Sanofi's wholly owned subsidiary."
- [confirms] ABL Bio (KO, news, published 2022-01-12) https://ablbio.com/kr/company/news_view/437: "ABL Bio signed an ABL301 co-development and license deal with Sanofi worth up to USD 1.06bn, including a USD 75m upfront and USD 45m near-term milestones."

Reverse side: https://valuechain.wiki/abl-bio/suppliers.md · Ripple: https://valuechain.wiki/abl-bio/ripple.md

---
Full node: https://valuechain.wiki/abl-bio.md · JSON: https://valuechain.wiki/abl-bio.json